- $69.15m
- $60.65m
- $58.44m
Brief: Lensar Inc - first patients treated with Lensar’S® Ally™ adaptive cataract treatment system
Lensar Inc Reports Results For The Quarter Ended In June: Earnings Summary
Brief: Lensar Reports Second Quarter 2022 Financial Results
Brief: LENSAR Expects To Place 8-12 Ally Systems In Controlled And Targeted Initial Launch
U.S. STOCKS ON THE MOVE-Choice Hotels International Inc, Campbell Soup, Day One Biopharmaceuticals
U.S. STOCKS ON THE MOVE-IMAX Corp, Volta, Ekso Bionics Holdings
U.S. STOCKS ON THE MOVE-Electric Last Mile Solutions, bluebird bio, Duke Realty Corp
LENSAR jumps as cataract surgery system wins FDA approval
Brief: Lensar Receives U.S. FDA Clearance Of Ally Adaptive Cataract Treatment System
Lensar Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Lensar Reports First Quarter 2022 Financial Results And Provides Business Update
Lensar Inc Expected To Post A Loss Of 73 Cents A Share: Earnings Preview
Lensar Inc Expected To Post A Loss Of 73 Cents A Share: Earnings Preview
Lensar Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Lensar Reports Fourth Quarter And Full Year 2021 Financial Results
Lensar Inc Expected To Post A Loss Of 52 Cents A Share: Earnings Preview
Brief: Lensar Announces U.S. FDA Acceptance Of 510(K) Submission For Ally
Lensar Inc Reports Results For The Quarter Ended In September: Earnings Summary
Lensar Inc Reports Results For The Quarter Ended In June: Earnings Summary